Cavallini Claudio, Savonitto Stefano, Violini Roberto, Arraiz Gustavo, Plebani Mario, Olivari Zoran, Rubartelli Paolo, Battaglia Salvatore, Niccoli Luigi, Steffenino Giuseppe, Ardissino Diego
Ospedale Ca' Foncello, Divisione di Cardiologia, Piazza Ospedale 1, 31100 Treviso, Italy.
Eur Heart J. 2005 Aug;26(15):1494-8. doi: 10.1093/eurheartj/ehi173. Epub 2005 Mar 1.
Retrospective studies and post hoc analyses have suggested that mild elevations in the creatine kinase-MB (CK-MB) isoenzyme following percutaneous coronary intervention (PCI) may be associated with an increased risk of death in the long term. However, this finding is still controversial, and the prognostic significance of elevations of more sensitive markers of myocardial damage, such as the cardiac troponins, has not been established. In this multicentre prospective cohort study, we evaluated the influence of post-procedural elevations of CK-MB and troponin I (cTnI) on long-term mortality.
The CK-MB and PCI study included 3494 consecutive patients undergoing PCI from February 2000 to October 2000 in 16 Italian tertiary centres. Blood samples were collected at baseline, and at 8-12 and 18-24 h after the procedure, and were analysed in a core biochemistry laboratory. CK-MB elevation was detected in 16% of the patients, and was associated with increased 2-year mortality [7.2 vs. 3.8%; odds ratio (OR): 1.9; 95% confidence interval (CI): 1.3-2.8; P<0.001). The degree of CK-MB elevation (peak CK-MB ratio) independently predicted the risk of death (adjusted OR per unit: 1.04; 95% CI: 1.01-1.07; P=0.009). A cTnI elevation was detected in 44.2% of the cases and was not associated with a significant increase in mortality (4.9 vs. 4.0%; OR: 1.2; 95% CI: 0.9-1.7; P=0.2).
Post-procedural elevations of CK-MB, but not cTnI, influence 2-year mortality.
回顾性研究和事后分析表明,经皮冠状动脉介入治疗(PCI)后肌酸激酶同工酶MB(CK-MB)轻度升高可能与长期死亡风险增加有关。然而,这一发现仍存在争议,心肌损伤更敏感标志物如心肌肌钙蛋白升高的预后意义尚未明确。在这项多中心前瞻性队列研究中,我们评估了PCI术后CK-MB和肌钙蛋白I(cTnI)升高对长期死亡率的影响。
CK-MB与PCI研究纳入了2000年2月至2000年10月在意大利16个三级中心连续接受PCI的3494例患者。在基线、术后8 - 12小时和18 - 24小时采集血样,并在核心生物化学实验室进行分析。16%的患者检测到CK-MB升高,且与2年死亡率增加相关[7.2%对3.8%;比值比(OR):1.9;95%置信区间(CI):1.3 - 2.8;P<0.001]。CK-MB升高程度(峰值CK-MB比值)独立预测死亡风险(每单位调整后OR:1.04;95%CI:1.01 - 1.07;P = 0.009)。44.2%的病例检测到cTnI升高,且与死亡率显著增加无关(4.9%对4.0%;OR:1.2;95%CI:0.9 - 1.7;P = 0.2)。
PCI术后CK-MB升高而非cTnI升高影响2年死亡率。